An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Academic Article uri icon

Overview

abstract

  • Metastasis is responsible for the majority of prostate cancer-related deaths; however, little is known about the molecular mechanisms that underlie this process. Here we identify an oncogene-tumor suppressor cascade that promotes prostate cancer growth and metastasis by coordinately activating the small GTPase Ras and nuclear factor-kappaB (NF-kappaB). Specifically, we show that loss of the Ras GTPase-activating protein (RasGAP) gene DAB2IP induces metastatic prostate cancer in an orthotopic mouse tumor model. Notably, DAB2IP functions as a signaling scaffold that coordinately regulates Ras and NF-kappaB through distinct domains to promote tumor growth and metastasis, respectively. DAB2IP is suppressed in human prostate cancer, where its expression inversely correlates with tumor grade and predicts prognosis. Moreover, we report that epigenetic silencing of DAB2IP is a key mechanism by which the polycomb-group protein histone-lysine N-methyltransferase EZH2 activates Ras and NF-kappaB and triggers metastasis. These studies define the mechanism by which two major pathways can be simultaneously activated in metastatic prostate cancer and establish EZH2 as a driver of metastasis.

publication date

  • February 14, 2010

Research

keywords

  • Genes, Tumor Suppressor
  • Genes, ras
  • NF-kappa B
  • Oncogenes
  • Prostatic Neoplasms
  • ras GTPase-Activating Proteins

Identity

PubMed Central ID

  • PMC2903662

Scopus Document Identifier

  • 77749297990

Digital Object Identifier (DOI)

  • 10.1038/nm.2100

PubMed ID

  • 20154697

Additional Document Info

volume

  • 16

issue

  • 3